# A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer

> **NCT05859750** · PHASE2 · RECRUITING · sponsor: **Akeso** · enrollment: 78 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** AK104
- **DRUG:** AK104
- **DRUG:** Gemcitabine
- **DRUG:** Nab-Paclitaxel
- **DRUG:** Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate
- **DRUG:** Oxaliplatin + Irinotecan + 5-Fluorouracil/Leucovorin

## Key facts

- **NCT ID:** NCT05859750
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-25
- **Primary completion:** 2025-06
- **Final completion:** 2025-12
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2024-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05859750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05859750, "A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05859750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*